Equities
  • Price (EUR)232.80
  • Today's Change-1.70 / -0.72%
  • Shares traded110.00
  • 1 Year change+8.08%
  • Beta--
Data delayed at least 15 minutes, as of Jan 21 2022 14:49 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through three business segments: BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including medication delivery solutions, medication management solutions, diabetes care and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The BD Interventional segment provides vascular, urology, oncology and surgical specialty products.

  • Revenue in USD (TTM)20.25bn
  • Net income in USD2.00bn
  • Incorporated1906
  • Employees75.00k
  • Location
    Becton Dickinson and Co1 Becton DrFRANKLIN LAKES 07417-1815United StatesUSA
  • Phone+1 (201) 847-6800
  • Websitehttp://www.bd.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
BDX:NYQ since
announced
Transaction
value
Scanwell Health IncDeal completed21 Dec 202121 Dec 2021Deal completed4.84%--
Tissuemed LtdDeal completed09 Dec 202109 Dec 2021Deal completed7.38%--
Venclose IncDeal completed02 Dec 202102 Dec 2021Deal completed9.50%--
Tepha IncDeal completed27 Jul 202127 Jul 2021Deal completed6.09%--
Velano Vascular IncDeal completed20 Jul 202120 Jul 2021Deal completed7.03%--
Data delayed at least 15 minutes, as of Jan 21 2022 21:10 GMT.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.